Advertisement

Topics

Human medicines European public assessment report (EPAR): Arzerra, ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 19/04/2010, Revision: 16, Status: Withdrawn

06:26 EDT 10 May 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Arzerra, ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 19/04/2010, Revision: 16, Status: Withdrawn

Original Article: Human medicines European public assessment report (EPAR): Arzerra, ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 19/04/2010, Revision: 16, Status: Withdrawn

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Arzerra, ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 19/04/2010, Revision: 16, Status: Withdrawn"

Advertisement
Quick Search
Advertisement
Advertisement